Prognosis for Don Draper: Not Good
A study challenges the idea that “bottoming out” makes one more receptive to getting help for an addiction.
Browsing Tag
Addiction
149 posts
The Trippy New Era: Returning to Hallucinogens as a Treatment for Addiction
LSD, ecstasy, and magic mushrooms are helping people face death, cope with trauma, and quit booze and smokes. Can these drugs revolutionize addiction treatment, or is it all just tangerine trees and marmalade skies?
The Only Place Where They’ll Inject You With Heroin for Free
In downtown Vancouver, government-approved researchers are providing drug addicts with heroin to see if a dependable supply of the substance will improve lives.
We Are All Internet Addicts Now—Just Don’t Call It That
New research has many (on the Internet) talking about the evolutionary causes of our "addiction" to the Internet, but it's not an addiction, at least not in the way we're used to applying the label.
The ‘DSM-5’: Introducing the Latest Edition of Psychiatry’s Diagnostic Bible
What does it mean that the American Psychiatric Association is switching from Roman numerals to Arabic? And will the critics ever be won over?
Should We Dump the DSM?
Gary Greenberg's new book skewers the inner workings of the DSM just three weeks before the latest version is scheduled to be released.
When It Comes to Addiction, the DSM-5 Gets It Right, But…
The new spectrum approach to substance use disorder will improve diagnoses. But the revision could have gone even further in keeping up with the data.
DSM-5: The End of One-Size-Fits-All Addiction Treatment?
When the dust of debate settles, the new revision's benefits should be clear: good science, better diagnoses, more individualized care.
A Shot in the Dark: Can Vivitrol Help Us Control Our Addictions?
Evaluating Vivitrol, the newest anti-addiction drug—actually an injectable form of an old pill. It's definitely better than nothing. But is it $1,100 a month better?
Pharma’s Fraught Quest for Addiction Medication Pay Dirt
Examining the medical, moral, and monetary decisions that Alkermes made to bring its drug Vivitrol to market—including a controversial trial in Russia. Are the critics right to cry foul?